These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9368796)

  • 1. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Eur J Clin Chem Clin Biochem; 1997 Oct; 35(10):775-9. PubMed ID: 9368796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):504-8. PubMed ID: 9401831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover trials should not be used to test one treatment against another treatment with a totally different chemical class/mode of action.
    Cleophas TJ
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1503-8. PubMed ID: 11185673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.
    Parienti JJ; Kuss O
    Contemp Clin Trials; 2007 May; 28(3):316-23. PubMed ID: 17110172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of alternative statistical models for crossover studies to demonstrate caffeine adjuvancy in the treatment of tension headache.
    Koch GG; Amara IA; MacMillan J
    J Biopharm Stat; 1994 Nov; 4(3):347-410. PubMed ID: 7881452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple analysis of crossover studies with one-group interaction.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):322-7. PubMed ID: 7582382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A note on the sample size determination in two-period repeated measurements crossover design with application to clinical trials.
    Yue LQ; Roach P
    J Biopharm Stat; 1998 Nov; 8(4):577-84. PubMed ID: 9855035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tests for the analysis of variance of crossover designs with correlated errors.
    Bellavance F; Tardif S; Stephens MA
    Biometrics; 1996 Jun; 52(2):607-12. PubMed ID: 8672705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CrossOver: an algorithm for the construction of efficient cross-over designs.
    John JA; Russell KG; Whitaker D
    Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of two-stage test statistic in the two-period crossover trials.
    Wang SJ; Hung HM
    Biometrics; 1997 Sep; 53(3):1081-91. PubMed ID: 9333341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of extensions of bivariate rank sum statistics to the crossover design to compare two treatments through four sequence groups.
    Kawaguchi A; Koch GG; Ramaswamy R
    Biometrics; 2009 Sep; 65(3):979-88. PubMed ID: 19173698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian analysis of the two-period crossover design for clinical trials.
    Grieve AP
    Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials: relevance of correlation between treatment modalities.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):670-5. PubMed ID: 8963485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The place of the crossover design in infertility trials: a maximum likelihood approach.
    McDonnell J; Goverde AJ; Vermeiden JP
    Hum Reprod; 2004 Nov; 19(11):2537-44. PubMed ID: 15459169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using the maximum test statistic in the two-period crossover clinical trial.
    Willan AR
    Biometrics; 1988 Mar; 44(1):211-8. PubMed ID: 3358989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the covariance structure in pharmacokinetic crossover trials.
    Lindsey JK; Wang J; Byrom WD; Jones B
    J Biopharm Stat; 1999 Aug; 9(3):439-50. PubMed ID: 10473030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Handling of baseline measurements in the analysis of crossover trials.
    Chen X; Meng Z; Zhang J
    Stat Med; 2012 Jul; 31(17):1791-803. PubMed ID: 22715129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternative analysis for crossover studies that accounts for between-group disparities in drug response--corrigenda.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):353. PubMed ID: 9660046
    [No Abstract]   [Full Text] [Related]  

  • 20. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.